Neurology

Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan

Retrieved on: 
onsdag, april 17, 2024
Seizure, Marketing, NHI, Eisai, Patient, AMPA, National health insurance, Neurology, AED, Epilepsy, Pharmaceutical industry

TOKYO, Apr 17, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) for intravenous (IV) infusion has been launched in Japan.

Key Points: 
  • TOKYO, Apr 17, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) for intravenous (IV) infusion has been launched in Japan.
  • The injection formulation of Fycompa received manufacturing and marketing approval on January 18, 2024 and was included in the Japan's National Health Insurance (NHI) Drug Price List today.
  • Two oral formulations of Fycompa are available in Japan: a tablet and a fine granule formulation.
  • Since Fycompa is the only AMPA receptor antagonist-based AED, Eisai developed this injection formulation to meet the needs of patients who are unable to use oral administration, and leading to the launch today.

French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics

Retrieved on: 
onsdag, april 3, 2024
Parkinson's disease, Ecosystem, Psychiatry, Health, Eisai, Loxapine, Dependent territory, CNX, Patient, Global Health, Neurology, Marketing, Therapy, Anxiety, Pharmaceutical industry

TOKYO, Apr 3, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that its French sales subsidiary Eisai S.A.S.

Key Points: 
  • TOKYO, Apr 3, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that its French sales subsidiary Eisai S.A.S.
  • entered into an agreement to transfer the rights in France, the French Overseas Territories and Algeria (the "Territory") for the antipsychotic, "Loxapac" (generic name: loxapine) and the Parkinson's disease treatment "Parkinane LP" (generic name: trihexyphenidyl hydrochloride) to CNX Therapeutics Limited.
  • Eisai anticipates no changes to its consolidated financial forecast for the period ending March 31, 2024.
  • acquired the rights to both treatments in the Territory in July 2002 and has been marketing them since.

Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical

Retrieved on: 
fredag, mars 29, 2024
Health, Marketing, Vertigo, Eisai, Ecosystem, Patient, Anxiety, Global Health, Neurology, Pharmaceutical industry

TOKYO, Mar 29, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon (generic name: betahistine mesilate) and muscle relaxant Myonal (generic name: eperisone hydrochloride) in Japan to Kaken Pharmaceutical Co., Ltd.

Key Points: 
  • TOKYO, Mar 29, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon (generic name: betahistine mesilate) and muscle relaxant Myonal (generic name: eperisone hydrochloride) in Japan to Kaken Pharmaceutical Co., Ltd.
    Merislon and Myonal have been widely used by patients in Japan for a long time since their launch in 1969 and 1983, respectively.
  • Eisai has determined that divesting rights for these products to Kaken, which has strengths in the products' disease areas, is the most optimal choice to ensure them to continue contributing to a greater number of patients.
  • Eisai anticipates no changes to its consolidated financial forecast for the period ending March 31, 2024.
  • Driven by our hhc concept, Eisai strives to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas: Neurology, Oncology and Global Health.

Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024

Retrieved on: 
fredag, mars 29, 2024
Cyclopropane, PSJ, Safety, Sleep, Royal Pharmaceutical Society, Lemborexant, Research, Insomnia, Protein, Development, Alzheimer's disease, Disease, Patient, Executive director, AMPA, Neurology, Medicine, Drug discovery, Drug development, Eribulin, CEG, Pharmaceutical industry

TOKYO, Mar 29, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that drug discovery research conducted on lemborexant (brand name: Dayvigo), the dual orexin receptor antagonist discovered by Eisai, has been honored with The Pharmaceutical Society of Japan (PSJ) Award for Drug Research and Development 2024 by the PSJ.

Key Points: 
  • TOKYO, Mar 29, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that drug discovery research conducted on lemborexant (brand name: Dayvigo), the dual orexin receptor antagonist discovered by Eisai, has been honored with The Pharmaceutical Society of Japan (PSJ) Award for Drug Research and Development 2024 by the PSJ.
  • The PSJ Award for Drug Research and Development is one of a series of awards presented by the PSJ and is dedicated to researchers who have conducted outstanding research work that has contributed to medicine through the innovative development of a pharmaceutical drug or applicable technology related to the pharmaceutical sciences.
  • Award recipients are evaluated by the PSJ based on the ingenuity of the research itself as well as the effectiveness and safety of the related pharmaceutical product(s) or the innovativeness of the related medical treatment or treatment technology.
  • Lemborexant is currently approved for the indication of insomnia in over 15 countries, including Japan, the U.S., Canada, Australia, and countries in Asia.

Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results

Retrieved on: 
torsdag, maj 9, 2024
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Clinical Trials, FDA, COYA, University, FTD, Society, Cancer, Viral, Laboratory, Survival, Coya, Conference, GM-CSF, Nebraska Medicine, IND, Granulocyte-macrophage colony-stimulating factor, Pharmacology, Frontotemporal dementia, Patient, Caregiver, Medulla oblongata, Serum, ALS, Diagnosis, PD, Therapy, Pharmaceutical industry

Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the quarter ended March 31, 2024.

Key Points: 
  • Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the quarter ended March 31, 2024.
  • Additionally, clinical data from the previously completed investigator-initiated trial in patients with ALS is also anticipated in the second quarter.
  • 2 investigator-initiated trial involving COYA 301, or low-dose IL-2 alone, is expected in the summer of 2024.
  • As of March 31, 2024, Coya had cash and cash equivalents of $36.0 million.

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results

Retrieved on: 
torsdag, maj 9, 2024
Biotechnology, Neurology, Health, Genetics, Pharmaceutical, STAC, FDA, CTA, Haemophilia, Enzyme replacement therapy, Kite, Investment, Nav1.7, Fabry disease, Poster, Disease, ERT, Sigma-Aldrich, STAAR, Health care, MAA, Partnership, Sangamo Therapeutics, MINT, AAV, Ligand Pharmaceuticals, IND, Tauopathy, Novartis, DNA, Patient, Pivotal, DSM-IV codes, EMA, Prion, BBB, Genome, BLA, MHRA, Manuscript, BioRxiv, Capsid, Modularity, Biogen, Therapy, Food and Drug Administration, European Medicines Agency, Gene, Pharmaceutical industry

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported business highlights and first quarter 2024 financial results.

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported business highlights and first quarter 2024 financial results.
  • “We are pleased with the progress being made in business development discussions across our portfolio, including our Fabry disease program.
  • An IND submission is expected in the fourth quarter of 2024.
  • Revenues for the first quarter ended March 31, 2024 were $0.5 million, compared to $158.0 million for the same period in 2023.

Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia

Retrieved on: 
torsdag, maj 9, 2024
Biotechnology, General Health, Pharmaceutical, Health, Spasticity, Pain, FDA, Patient, CMS, Headache, Label, Death, Speech, ASPEN, Dysphagia, Therapy, Torticollis, Physician, Hubli railway division, Neurology, Medicare, Neurotoxin, MBA, Injection, Pharmaceutical industry

The launch marks Revance’s entry into the large and growing U.S. therapeutics neurotoxin market.

Key Points: 
  • The launch marks Revance’s entry into the large and growing U.S. therapeutics neurotoxin market.
  • “DAXXIFY provides a significant opportunity for Revance and marks the culmination of our decades-long mission to bring true innovation to the therapeutics market.
  • Following the FDA’s approval of DAXXIFY for cervical dystonia in August 2023, Revance launched the DAXXIFY cervical dystonia PrevU early experience program with the objective of optimizing treatment outcomes for patients and ensuring smooth practice integration.
  • DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines.

Tool To Warn Of Concussions Wins Grand Prize At Sunstone CSU Startup Launch Competition 2024

Retrieved on: 
torsdag, maj 9, 2024
Technology, Medical Devices, Professional Services, Foundation, Philanthropy, Neurology, Biking, Cycling, Sports, Wearables, Mobile Technology, Health, IOT (Internet of Things), Apps, Applications, Start-Up, Football, General Sports, Consumer Electronics, Artificial Intelligence, San Francisco State University, Concussion, PCB, Foundation (nonprofit), SCF, School, Prize, Radar, Entrepreneurship, Artificial intelligence, Annenberg Foundation, Environment, California State University, Chico, Sacramento, California, Hackathon, Safeguard, Sunstone, Dave & Buster's, California State University, California State University, Sacramento, Rock (geology), Atmosphere, Financial Times, Grand Finale, Medical device

The young entrepreneurs were vying for $200,000 in prize money from the Sunstone Community Fund, the charitable donor-advised fund which raises money to support entrepreneurship at its earliest stages.

Key Points: 
  • The young entrepreneurs were vying for $200,000 in prize money from the Sunstone Community Fund, the charitable donor-advised fund which raises money to support entrepreneurship at its earliest stages.
  • Andrew Jenkins said Concussion Coach’s journey to the Grand Prize didn’t start auspiciously.
  • Next year’s Sunstone CSU Startup Launch Competition will be at San Francisco State University in Spring 2025.
  • In the latest Pitchbook rankings, Sunstone Management was #15 in the third quarter of 2023 nationally, and #18 in the fourth quarter .

Veterinary Imaging Market Size Projected to Reach USD 4,306.6 Million by 2034: Future Market Insights, Inc.

Retrieved on: 
torsdag, maj 9, 2024
Online, Area studies, Hospital, MHealth, Publication, News, Animal, Cardiology, Software, Health care, MEA, Elective surgery, Research, Medication, Medical device, Neurology, MRI, Magnetic resonance imaging, Compound annual growth rate, 2D, Associate, Clinic, Journal, FMI, Radiography, Competitive intelligence, Pet industry

NEWARK, Del., May 9, 2024 /PRNewswire/ -- The veterinary imaging market has been gaining significant traction globally, with a projected value of USD 2,272.8 million in 2024 and an estimated value of USD 4,306.6 million by 2034, developing at a CAGR of 6.6%. The rising demand for animal healthcare services, growing pet ownership, and increasing awareness about the importance of animal health primarily drive this growth.

Key Points: 
  • Veterinary imaging equipment is further categorized as radiography (X-ray), ultrasound imaging, magnetic resonance imaging, computed tomography, video endoscopy imaging, and other systems.
  • From its estimated value of US$ 1,465.4 million in 2024, the market is expected to reach US$ 2,319.6 million by 2034.
  • According to recent research by Future Market Insights, app-based solutions dominate the market, holding a share of approximately 57.7% in 2022.
  • The in vitro diagnostics market is poised for steady growth, with a projected CAGR of 4.8% during the forecast period.

Veterinary Imaging Market Size Projected to Reach USD 4,306.6 Million by 2034: Future Market Insights, Inc.

Retrieved on: 
torsdag, maj 9, 2024
Online, Area studies, Hospital, MHealth, Publication, News, Animal, Cardiology, Software, Health care, MEA, Elective surgery, Research, Medication, Medical device, Neurology, MRI, Magnetic resonance imaging, Compound annual growth rate, 2D, Associate, Clinic, Journal, FMI, Radiography, Competitive intelligence, Pet industry

NEWARK, Del., May 9, 2024 /PRNewswire/ -- The veterinary imaging market has been gaining significant traction globally, with a projected value of USD 2,272.8 million in 2024 and an estimated value of USD 4,306.6 million by 2034, developing at a CAGR of 6.6%. The rising demand for animal healthcare services, growing pet ownership, and increasing awareness about the importance of animal health primarily drive this growth.

Key Points: 
  • Veterinary imaging equipment is further categorized as radiography (X-ray), ultrasound imaging, magnetic resonance imaging, computed tomography, video endoscopy imaging, and other systems.
  • From its estimated value of US$ 1,465.4 million in 2024, the market is expected to reach US$ 2,319.6 million by 2034.
  • According to recent research by Future Market Insights, app-based solutions dominate the market, holding a share of approximately 57.7% in 2022.
  • The in vitro diagnostics market is poised for steady growth, with a projected CAGR of 4.8% during the forecast period.